Bringing a Medical Device to the US Market: FDA Compliance Guide
Overview
Bringing a medical device to the US market requires navigating regulatory pathways enforced by the FDA Center for Devices and Radiological Health (CDRH). Manufacturers must first classify their device into Class I, Class II, or Class III based on risk. Depending on classification, companies must select the appropriate premarket submission—such as a 510(k) Premarket Notification, Premarket Approval (PMA), or De Novo request. Following premarket authorization, companies must complete mandatory FDA establishment registration, device listing, and maintain ongoing post-market surveillance via MedWatch and Quality System Regulations (21 CFR Part 820).
Launch Your Medical Device in the U.S. Market
The global medical technology sector continues to experience rapid innovation, with more than 200 million medical devices in use worldwide. For manufacturers seeking commercial entry into the United States—the world’s largest healthcare market—this expansion brings significant strategic opportunities alongside complex legal and regulatory hurdles.
Introducing medical devices into the US market necessitates a detailed understanding of requirements established by the U.S. Food and Drug Administration (FDA). From risk classification and Design Control documentation to electronic submissions and post-market tracking, staying aligned with FDA regulations is essential to streamline market clearance and avoid costly launch delays.
Step 1: Determining US Medical Device Classification
The FDA regulates medical devices through the Center for Devices and Radiological Health (CDRH). The CDRH categorizes all medical devices into one of three risk-based regulatory classes. Determining the correct device classification is the foundational step that dictates project timelines, clinical trial requirements, and overall compliance costs.
| Device Class | Risk Profile | Regulatory Controls Required | Primary Submission Pathway |
| Class I | Low to Moderate Risk | General Controls (Most exempt from premarket submission; select devices require 510(k)) | 510(k) Exempt / 510(k) |
| Class II | Moderate to High Risk | General Controls & Special Controls (Requires demonstration of substantial equivalence) | 510(k) Premarket Notification |
| Class III | High Risk (Life-sustaining, supporting, or implantable) | General Controls & Premarket Approval (Requires clinical trial data proving safety & effectiveness) | Premarket Approval (PMA) |
| De Novo Pathway | Low to Moderate Risk (Novel technology with no predicate) | General & Special Controls (Establishes a new classification and predicate for future devices) | De Novo Request |
How to Identify Your Device Classification
To identify your specific product classification, search the FDA Product Classification Database. This database allows manufacturers to search by product codes, device names, regulation numbers, or review panels to uncover relevant regulatory controls, product codes, and submission requirements.
Step 2: Selecting and Preparing the Correct Premarket Submission
Once you determine your device class, you must select the appropriate premarket submission route to secure FDA authorization:
1. 510(k) Premarket Notification (Class II & Select Class I)
The primary objective of a 510(k) submission is to demonstrate that your medical device is substantially equivalent to a legally marketed predicate device in the United States.
You must compare intended use, technological characteristics, and performance specifications against the predicate.
While laboratory performance and bench testing are standard, human clinical trials are rarely required for a 510(k).
The standard FDA review window for a 510(k) is 30 to 90 days, though administrative hold requests for additional information can extend timelines.
2. Premarket Approval – PMA (Class III)
Class III devices—such as implantable pacemakers, vascular stents, and life-supporting equipment—pose higher risk to patients and require a Premarket Approval (PMA) application.
The PMA standard is significantly higher than a 510(k).
Manufacturers must present comprehensive scientific evidence, including human clinical trials and extensive laboratory testing, to prove safety and effectiveness.
The FDA review period for a PMA application is officially 180 days, though thorough scientific evaluations often involve additional review cycles.
3. De Novo Classification Pathway
For novel devices that present low-to-moderate risk but lack an existing predicate device, manufacturers can utilize the De Novo pathway.
The De Novo process establishes a brand-new device classification without requiring comparison to a predicate.
Applicants must present a comprehensive risk mitigation strategy demonstrating that general and special controls adequately ensure safety and performance.
Step 3: Preparing Technical Documentation and Design Controls
Preparing a robust premarket submission requires compiling structured design, quality, and testing documentation tailored to your product risk profile:
Design Controls (21 CFR Part 820 / ISO 13485): Development of a thorough Design History File (DHF), incorporating user needs, design inputs, design outputs, design verification, design validation, design reviews, and design changes.
Risk Management: Detailed risk planning and risk evaluation data conforming to ISO 14971 standards, including usability engineering and clinical safety evaluations.
Non-Clinical & Bench Testing: Electrical safety, biocompatibility, software validation, and mechanical testing protocols.
Device Labeling & Packaging: Development of user manuals, outer package labeling compliant with FDA medical device labeling standards, and electronic Instructions for Use (eIFU) integration where applicable. For software-driven products, manufacturers must also reference updated FDA guidance on AI-enabled medical devices.
Preparing a 510(k) dossier or evaluating a De Novo submission?
Consult our FDA regulatory experts at Operon Strategist to build your entry roadmap.
Step 4: FDA Submission and Administrative Review
After compiling all required technical and clinical documentation:
Submit Application: Send an electronic copy (eCopy / eSTAR format) to the FDA along with required FDA user fees.
Administrative Review (Refuse to Accept): The FDA performs an initial administrative review to determine if the dossier is sufficiently complete to enter substantive scientific evaluation.
Interactive Review: During the substantive review period (ranging from 90 to 180 days depending on the pathway), FDA lead reviewers communicate interactively with applicants to address technical questions, request data clarifications, or evaluate testing methods.
Step 5: Establishment Registration and Device Listing
Securing 510(k) clearance or PMA approval does not automatically grant authorization to begin commercial distribution. Before selling medical devices in the U.S., companies must complete mandatory administrative registrations:
FDA Facility Registration: Establishments that manufacture, package, label, or process medical devices for distribution in the U.S. must register their facility annually with the FDA under 21 CFR Part 807.
Medical Device Listing: All authorized medical devices must be officially listed under the company’s FDA establishment registration profile.
International Compliance: Overseas manufacturers importing devices into the U.S. must also designate a U.S. Agent for FDA communications.
Step 6: Post-Market Surveillance and Quality Management
Maintaining compliance in the United States extends well beyond initial commercial launch. Medical device manufacturers must uphold ongoing post-market controls:
Quality System Regulation (QSR / 21 CFR Part 820): Continuous compliance with Quality Management System standards during commercial manufacturing and distribution.
MedWatch Reporting: Active monitoring and reporting of adverse events, product malfunctions, non-conformances, or safety concerns using the FDA’s online MedWatch portal.
Post-Market Surveillance & Audits: Participation in independent FDA post-market inspections and ongoing risk evaluation over the product lifecycle.
How Operon Strategist Can Help
Successfully bringing a medical device to the U.S. market requires specialized technical insight and continuous alignment with evolving FDA standards. Operon Strategist provides comprehensive regulatory consulting to guide medical device manufacturers worldwide:
Regulatory Strategy & Classification: Accurately identifying product codes, device classes, and optimal premarket pathways (510(k), PMA, De Novo, or HDE).
510(k) Dossier Preparation & Submission: Complete compilation of technical documentation, predicate identification, gap analysis, and interactive submission support.
QMS Implementation & Design Controls: Developing compliant Quality Management Systems aligned with 21 CFR Part 820 and ISO 13485:2016, including complete Design History File (DHF) creation.
FDA Establishment Registration & Listing: Direct assistance with annual facility registration, device listing, and official U.S. Agent representation.
Global Regulatory Expansion: Supporting cross-border regulatory approvals across Europe (EU MDR), UK (MHRA), India (CDSCO), and global markets.
Ensure Seamless Regulatory Compliance for Your Device
Get Your Medical Device Market-Ready with Expert Regulatory Support
FAQ's
How do I find the FDA classification for my medical device?
Search the FDA Product Classification Database using your product name, intended use, or product code to determine its device class (Class I, II, or III) and required submission type.
What is the main difference between an FDA 510(k) and a PMA?
A 510(k) requires proving substantial equivalence to an existing predicate device (typically for Class II devices), whereas a PMA requires independent clinical proof of safety and effectiveness (typically for Class III devices).
Does 510(k) clearance allow immediate sale of a medical device in the U.S.?
No. After obtaining 510(k) clearance, manufacturers must complete annual FDA Establishment Registration and Device Listing before commercially distributing the product.
What is the De Novo pathway used for?
The De Novo pathway provides a risk-based approval route for novel Class I or Class II medical devices that have low-to-moderate risk but no existing predicate device on the market.
How long does the FDA take to review a 510(k) submission?
The standard FDA review timeframe for a 510(k) application is 90 days, though total time may vary if the FDA requests additional technical or testing data during interactive review.